Assessing potential of psilocybin for depressive disorders
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
Expert Opinion on Investigational Drugs October 3, 2023 DOI: 10.1080/13543784.2023.2273493 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with depression, specifically those with treatment-resistant depression |
| Topics | Depression Psychedelic-assisted therapy Psilocybin |
| Keywords | Psilocybin, psychedelics Magic mushroom therapy Treatment-resistant depression trd Refractory depression |
| Citations | 10 |
| Key findings | Patients with treatment-resistant depression may be the most suitable candidates for psilocybin treatment at this time. |
Abstract
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Comparable studies
Other narrative reviews on psilocybin and psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development | 2018 | Review | |
| Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. | 2016 | Review | |
| Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy | 2021 | Systematized review | |
| The Emerging Field of Psychedelic Psychotherapy. | 2022 | Review | |
| Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications Participants in psychedelic therapy research aged 18–69 with varied backgrounds | 2020 | Rapid review | n = 180 |
Citations in the library
Cited by 9
- Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? European Archives of Psychiatry and Clinical Neuroscience February 27, 2024
- Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies. Journal of Neural Transmission May 1, 2024
- Beyond psychedelics: set and setting in general psychiatric practice. International Review of Psychiatry December 1, 2024
- Innovations in group‐based psilocybin‐assisted therapy of major depression in patients with cancer Cancer December 18, 2023
- Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches Expert Opinion on Drug Discovery January 31, 2025
and 4 more in the library
Cites 55
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 50 more in the library